Get it on Google Play

FDA approves Alpha Tau trial expansion for pancreatic cancer treatment

April 23, 2026 9:02 AM EDT Send to a Friend
Alpha Tau Medical Ltd. (NASDAQ: DRTS) announced that the FDA has approved an Investigational Device Exemption supplement to expand its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login